145 related articles for article (PubMed ID: 12488702)
1. Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease.
Piodi LP; Bardella M; Rocchia C; Cesana BM; Baldassarri A; Quatrini M
J Clin Gastroenterol; 2003 Jan; 36(1):22-5. PubMed ID: 12488702
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease.
Pearce CB; Duncan HD; Timmis L; Green JR
Eur J Gastroenterol Hepatol; 2000 Apr; 12(4):439-43. PubMed ID: 10783998
[TBL] [Abstract][Full Text] [Related]
3. Seroprevalence of Helicobacter pylori infection in inflammatory bowel disease: is Helicobacter pylori infection a protective factor?
Väre PO; Heikius B; Silvennoinen JA; Karttunen R; Niemelä SE; Lehtola JK; Karttunen TJ
Scand J Gastroenterol; 2001 Dec; 36(12):1295-300. PubMed ID: 11761020
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Helicobacter pylori infection and related upper gastrointestinal lesions in patients with inflammatory bowel diseases. A cross-sectional study with matching.
Parente F; Molteni P; Bollani S; Maconi G; Vago L; Duca PG; Rembacken B; Axon AT; Bianchi Porro G
Scand J Gastroenterol; 1997 Nov; 32(11):1140-6. PubMed ID: 9399396
[TBL] [Abstract][Full Text] [Related]
5. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine.
el-Omar E; Penman I; Cruikshank G; Dover S; Banerjee S; Williams C; McColl KE
Gut; 1994 Oct; 35(10):1385-8. PubMed ID: 7959192
[TBL] [Abstract][Full Text] [Related]
6. [Helicobacter pylori and nonspecific intestinal inflammation].
Münzová H; Dítĕ P; Sevcíková I; Dolina J; Novotný I; Kunovská M
Vnitr Lek; 2000 Dec; 46(12):839-42. PubMed ID: 11214362
[TBL] [Abstract][Full Text] [Related]
7. Inverse correlation between Helicobacter pylori infection and inflammatory bowel disease.
Halme L; Rautelin H; Leidenius M; Kosunen TU
J Clin Pathol; 1996 Jan; 49(1):65-7. PubMed ID: 8666689
[TBL] [Abstract][Full Text] [Related]
8. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
9. The prevalence of Helicobacter pylori infection in inflammatory bowel disease in China: A case-control study.
Ding ZH; Xu XP; Wang TR; Liang X; Ran ZH; Lu H
PLoS One; 2021; 16(3):e0248427. PubMed ID: 33711050
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of Helicobacter pylori gastritis in newly diagnosed children with inflammatory bowel disease.
Roka K; Roubani A; Stefanaki K; Panayotou I; Roma E; Chouliaras G
Helicobacter; 2014 Oct; 19(5):400-5. PubMed ID: 24827117
[TBL] [Abstract][Full Text] [Related]
11. Helicobacter pylori eradication therapy is not associated with the onset of inflammatory bowel diseases. A case-control study.
Rosania R; Von Arnim U; Link A; Rajilic-Stojanovic M; Franck C; Canbay A; Malfertheiner P; Venerito M
J Gastrointestin Liver Dis; 2018 Jun; 27(2):119-125. PubMed ID: 29922755
[TBL] [Abstract][Full Text] [Related]
12. [The prevalence of Helicobacter pylori infection in Korean patients with inflammatory bowel disease, a multicenter study].
Song MJ; Park DI; Hwang SJ; Kim ER; Kim YH; Jang BI; Lee SH; Ji JS; Shin SJ
Korean J Gastroenterol; 2009 Jun; 53(6):341-7. PubMed ID: 19556840
[TBL] [Abstract][Full Text] [Related]
13. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
Terdiman JP; Steinbuch M; Blumentals WA; Ullman TA; Rubin DT
Inflamm Bowel Dis; 2007 Apr; 13(4):367-71. PubMed ID: 17206695
[TBL] [Abstract][Full Text] [Related]
14. Clinical onset of the Crohn's disease after eradication therapy of Helicobacter pylori infection. Does Helicobacter pylori infection interact with natural history of inflammatory bowel diseases?
Jovanovic IR; Milosavjevic TN; Jankovic GP; Micev MM; Dugalic PD; Saranovic D; Ugljesic MM; Popovic DV; Bulajic MM
Med Sci Monit; 2001; 7(1):137-41. PubMed ID: 11208510
[TBL] [Abstract][Full Text] [Related]
15. Helicobacter pylori prevalence and clinical significance in patients with quiescent Crohn's disease.
Lahat A; Kopylov U; Neuman S; Levhar N; Yablecovitch D; Avidan B; Weiss B; Ben-Horin S; Eliakim R;
BMC Gastroenterol; 2017 Feb; 17(1):27. PubMed ID: 28193167
[TBL] [Abstract][Full Text] [Related]
16. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
Bernstein CN; Nugent Z; Blanchard JF
Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
[TBL] [Abstract][Full Text] [Related]
17. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
[TBL] [Abstract][Full Text] [Related]
18. Lower prevalence of Helicobacter pylori infection in patients with inflammatory bowel disease but not with chronic obstructive pulmonary disease - antibiotic use in the history does not play a significant role.
Prónai L; Schandl L; Orosz Z; Magyar P; Tulassay Z
Helicobacter; 2004 Jun; 9(3):278-83. PubMed ID: 15165265
[TBL] [Abstract][Full Text] [Related]
19. Inverse association between Helicobacter pylori and inflammatory bowel disease: myth or fact?
Kayali S; Gaiani F; Manfredi M; Minelli R; Nervi G; Nouvenne A; Leandro G; Di Mario F; De' Angelis GL
Acta Biomed; 2018 Dec; 89(9-S):81-86. PubMed ID: 30561399
[TBL] [Abstract][Full Text] [Related]
20. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
